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ABSTRACT 
Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) is a 15Kb enveloped 
positive-sense, single stranded RNA virus. More than two decades after the emergence of 
PRRSV, much is known about the viral genome, spread, and pathogenesis of the disease but 
our knowledge of the protective immune response of the host to the PRRS virus remains 
incomplete.  
Neutralizing antibodies that are produced late during the course of the infection play a 
significant role in clearing virus infection. One of the most effective ways for the virus to combat 
this immune response is to have mutants that can escape the neutralization antibody response. 
Various studies have been done to indicate that the envelope glycoprotein 5 bears a major 
neutralizing epitope. The ectodomain of glycoprotein 5 in PRRSV has a neutralization epitope 
which is flanked by three N-linked glycosylation sites, N34, N44 and N51. It is believed that 
these glycosylation sites play a role in glycan shielding which is a primary mechanism by which 
the virus evades neutralizing immune responses. Analysis of GP5 sequences of a subset of 
field strains showed that the N34 glycosylation site can shift to N33 or N35. Comparing these 
variations to the virus neutralization titers, we observed that the closer the glycosylation site 
(N35) was to the epitope,  the virus neutralizing titer was significantly lower than when the 
glycosylation site was further away (N33).  The purpose of this study was to study the 
association between the variation in glycosylation site and its effects on virus neutralization.  We 
hypothesized that the position of the glycosylation site is under selection, it alters the virus 
neutralization titer and is involved in virus neutralization escape. Mutations carrying the change 
in glycosylation site at N33, N34 and N35 were introduced into a full length cDNA clone. 
Western Blots confirmed that predicted glycosylated sites were in fact glycosylated. Serum 
neutralization assays were performed on glycosylation variant FL-12 constructs using antiserum 
raised against N34 FL-12. Variation in  location of the glycosylation site on the amino terminal 
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side of the putative GP5 neutralization epitope explains some of the variation in neutralization of 
field strains and could be a novel mechanism by which viruses are adapted to serologic 
selection. According to our findings, virus neutralization titers for N35 were higher than those for 
N33 or N34. 
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CHAPTER 1 
 
INTRODUCTION 
 
The Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) is an economically 
significant disease of swine and has spread worldwide since its discovery. PRRSV spreads very 
quickly and pigs are infected with the virus through various routes. Very little is known about the 
protective immune response of the host to the PRRS virus and unlike other viruses, PRRSV 
doesn’t have the same effect on the host immune system. Humoral immune response against 
the virus can be seen right after infection but doesn’t provide any protection against the virus. It 
has been previously studied that the presence of these non-neutralizing antibodies can aid in 
viral replication in alveolar macrophages. Neutralizing antibodies are produced late during the 
course of the infection but play a significant role in protection against PRRSV.  
PRRSV can modulate the host immune system to work to its benefit and this ability 
varies with different virus strains and isolates, making it very complicated to study these 
interactions. The delay in the induction of protective cellular and humoral immunity provides a 
window of time in which the virus can replicate and generate a distribution of related genotypes. 
This variation in genomes within a virus population is known as quasispecies and some of these 
mutations can be linked to the escape phenotype of the virus.  
One of the most effective ways for the virus to combat the immune system is to have 
mutants that can escape the neutralization antibody response. There is substantial evidence 
pointing to the presence of an epitope on the major envelope glycoprotein, GP5, which plays a 
role in inducing neutralizing antibodies. GP5 protein has multiple potential N-glycosylation sites 
– the first one is located in the hypervariable region at N34, the second and third at residues 
N44 and 51. Previous studies have shown that virus quasispecies lacking glycosylation sites at 
either N34 or N51 or in combination, had an enhanced sensitivity to neutralization antibodies 
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suggesting the absence of these glycan moieties increase the accessibility of the neutralizing 
epitope to specific antibodies. Continuing with this idea, out of all three glycosylation sites on 
GP5, only the N34 glycosylation site seemed to vary within a sample of field isolates. The 
glycan site would either move closer to the known neutralizing epitope at N35 or move further 
away at N33. In experiments correlating these different virus strains with their neutralization 
titer, we observed that when the N34 glycan site was further away (N33) from the epitope on 
GP5 it made the virus more susceptible to antibody mediated neutralization than when the 
glycan site was closer (N35) to the neutralization epitope. These results indicate that the glycan 
moiety at N34 could be playing a role in glycan shielding. To look into this phenomenon further, 
infectious clones were made with varying glycosylation site at N33, N34 and N35 and another 
one completely lacking the glycan site. Neutralization assays and growth kinetics of these 
different viruses were looked at to advance our understanding of the glycan moiety at N34 and 
its role in glycan shielding. We hypothesized that the position of these glycosylation sites is 
under selection and can alter the virus neutralization titer and is also involved in virus 
neutralization escape.  
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CHAPTER 2 
 
LITERATURE REVIEW 
 
PRRSV Pathogenesis  
  
In the late 1980's, veterinary clinicians in the USA noted the appearance of a previously 
unrecognized disease in swine herds. In the 1990's similar outbreaks were reported in Germany 
and by 1991 the disease had spread all over Europe. In 1991, investigators identified the 
etiologic agent of the disease as Porcine Reproductive and Respiratory Syndrome Virus 
(PRRSV) (Wensvoort, 1991). PRRSV is an enveloped positive-sense, single stranded RNA 
virus. It belongs to the Coronaviridae family which has properties similar to the Arteviridae family 
and is placed in the Nidovirales order (Virus research, 2010).  
The 15Kb RNA genome of the virus is capped at the 5' end and polyadenylated at the 3' 
end. The genome encodes nine open reading frames that are expressed through a set of 
subgenomic mRNAs'. Two open reading frames, ORF1a and ORF1b are translated using the 
full length viral RNA. ORFs1a and 1b take up almost two-thirds of the genome and encode for 
non-structural proteins (Fang, 2010). The two long polyproteins are cleaved by proteases to 
release 14 proteins which include – proteases, RNA dependent RNA polymerase, helicase and 
an endonuclease. ORFs 2 to 5 encode for the glycosylated membrane proteins. GP2a, GP3 and 
GP4 (ORFs 2-4) are the minor N-glycosylated membrane protein and ORF 5 encodes for the 
major envelope glycoprotein GP5. GP5 forms a heterodimer with M protein, which a non-
glycosylated envelope protein encoded by ORF6. ORF 7 encodes for N protein, a nucleocapsid 
protein, which is highly immunogenic in infected animals.  
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The clinical signs of PRRS vary with the strain of virus, the immune status of the herd 
and management factors (OIE, 2008). The age or the stage of the pig also affects the clinical 
signs of the disease. Clinical signs in adults can range anywhere from reduced appetite, fever, 
premature furrowing and abortion, death in up to 10% or more of sows, loss of balance, circling 
and following to one side. In affected liters PRRSV can manifest in pigs as still born, high 
preweaning mortality, mummified pigs, variably sized weak new-born and edema around the 
eyes (Rossow, 1998). And in weaned pigs, loss of appetite and lethargy, obvious failure to 
thrive, labored or rapid breathing and/or respiratory distress, blotchy reddening of the skin, 
rough hair coats are signs that can point to PRRS. PRRS is very variable in its clinical 
manifestations but infection can also be asymptomatic. Concurrent infections with other 
pathogens are also very common and can lead to severe respiratory failures (OIE, 2008).  
PRRSV spreads very quickly and can take only seven to ten days to spread throughout 
a herd. Pigs are infected by PRRSV by various routes but the probability of infection is dose 
dependent and also varies by mode of exposure (Molina, 2008). Pigs are extremely susceptible 
to transmission via parenteral exposure which include but are not limited to standard husbandry 
practices like tail docking, teeth clipping PRRSV is also present in the oral fluids for several 
weeks following infection, so normal pig behavior such as bites, cuts etc. can also result in its 
spread. Infected boars can also transmit PRRS virus in their semen (Prickett, 2008). Indirect 
transmission by inanimate objects or vectors has also been observed. One other route of PRRS 
virus spread is by airborne transmission (Kritas, 2004).  
The PRRS virus has spread world-wide with the exception of Australia, New Zealand, 
Finland, Norway, Sweden, and Switzerland since its discovery. Certain other countries are 
actively engaged in eradication campaigns. Chile has already accomplished that goal (OIE, 
2008). The economic impact of PRRS virus is devastating and can end up costing the swine 
industry millions every year. In USA the losses due to this disease amount to s $600 million 
annually (Zimmerman, 2008).  
 5 
 
Infection with PRRSV produces viremia with subsequent dissemination and viral 
replication in multiple organs. PRRS virus has a tropism for cells of the macrophage or 
monocyte lineage. The virus replicates mainly in macrophages of the lymphoid tissues and 
lungs in the acute phase of infection and persists in tonsil and lung macrophages (Chang, 
2002). PRRS virus antigen has been found in the resident macrophages of a variety of tissues, 
including muscle. PRRSV typically produces a multisystemic infection in pigs but gross lesions 
are only observed in respiratory and lymphoid tissues. In severe disease the cranioventral lobes 
of the lungs are most affected and appear mottled, tan and red, and fail to collapse. Lymph 
nodes are moderately to severely enlarged and tan in colour and, may be hemorrhagic with 
some strains. Under field conditions, most PRRS virus infected pigs are co-infected with one or 
more pathogens, which complicates the diagnosis of PRRS based on pathology (OIE, 2008). 
 
Immune Response to PRRSV 
  
More than two decades after the emergence of PRRSV, our understanding of the 
disease is nowhere near complete. Even though much is known about the viral genome, 
spread, pathogenesis of the disease, there are plenty of gaps that need to be filled. One aspect 
of the disease, which we know little about, is the protective immune response of the host to the 
PRRS virus. PRRSV unlike other viral infections doesn’t have the same effect on the host 
immune system. It modulates the host immune system to work to its benefit and this ability of 
the virus varies with different strains and isolates, making it even more complicated to study 
these interactions. 
The mechanism by which PRRSV modulates the host immune system is still in the 
process of being understood. Humoral response to PRRS virus is rapid but offers no protection 
to the host. Circulating antibodies against PRRSV are detected within 5-7 days of infection. 
Even though the rapid IgM and IgG response reach a peak at 14dpi (days post infection) and 
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can be detected till at least 42dpi, they do not protect against PRRSV infection (Ansari, 2006). 
Other diagnostic tests can detect antibodies against the N protein in PRRSV, which appear in 
the first week of infection and persist for months after the infection but again provide no 
protection. The early production of non-neutralizing antibodies may have a significant effect on 
the development of PRRS. It has been shown that non-neutralizing antibodies facilitate viral 
replication in alveolar macrophages, a phenomenon known as antibody-dependent 
enhancement (ADE). The non-neutralizing humoral response can act as a Trojan horse for 
PRRSV by coating the virus and enhancing the internalization of viral particles into 
macrophages (Mateau, 2008). 
Studies have shown that PRRSV is highly susceptible to the action of type 1 interferon 
(IFN) but the virus has the ability to reduce the induction of IFN- α. IFN-α is present at almost 
undetectable levels in lungs of pigs where PRRSV is actively replicating. Even though the 
mechanism by which PRRSV can inhibit IFN-α response is unknown, it is known that it inhibits 
the development of an effective T helper type 1 (Th1) immune response (Lopez, 2004). 
Neutralizing antibodies (NA) that are produced late during the course of infection do play 
a significant role in protecting against the PRRS virus. The onset of NA after experimental 
infection is known to be accompanied by clearance of the virus from circulation and from 
tissues. It is believed that the neutralizing antibody response correlates very well with the viral 
clearance in tissue. (Lopez, 2004). This leads to the question that if the neutralizing antibodies 
are so effective in the clearance of PRRS virus in the host then why is PRRSV still so 
widespread? 
PRRSV in nature has been shown to be a distribution of related genotypes. known as 
quasispecies (Goldberg, 2003). Quasispecies evolve from various mutations, some of which 
might be linked to the escape phenotype of the virus. When the protective neutralizing 
antibodies of the PRRS virus are produced in the host, these escape variants may occur but 
remain undetected. This gives the escape mutants an evolutionary advantage. The evolutionary 
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plasticity of such distributions could account for the notorious ability of PRRSV, like other RNA 
viruses to evade host immunity and to evolve novel clinical manifestations as can be seen in 
human immunodeficiency virus (HIV) and hepatitis C virus (Hep C) (Goldberg, 2003). Various 
studies on HIV have shown the diversification of quasispecies early in infection and subsequent 
selection which results in a favorable outcome for the virus. Essajee et al (2000) have shown 
that the antiviral immune response against HIV in adults drives the emergence of new variants 
as the virus evolves to escape it. Another study demonstrated an association between greater 
viral diversity and slower disease progression. But once the “best fit” virus is selected by 
dodging the immune system, it can persist and result in a chronic infection (Arnott, 2010). It is 
plausible that PRRSV behaves the same way in swine as HIV does in humans. However, very 
little is known about the principles, mechanisms and dynamics underlying the selection of 
escape variants in PRRSV. 
One of the most effective ways for the virus to combat the immune system is to have 
mutants that can escape the neutralization antibody response (Dimmock, 2007). Neutralizing 
antibodies block infection “by aggregation of virions, destabilization of the virion structure, 
inhibition of virion attachment to target cells, inhibition of the fusion of the virion lipid membrane 
with the membrane of the host cell, inhibition of the entry of the genome of non-enveloped 
viruses into the cell cytoplasm, inhibition of a function of the virion core through a signal 
transduced by an antibody, transcytosing IgA, and binding to nascent virions to block their 
budding or release from the cell surface” (Dimmock, 2007). The mechanism by which antibodies 
block infection depends on the antibody as well as the epitope on the virus with which it reacts. 
Since a virion typically bears numerous viral epitopes, a virus may be neutralized various ways 
and it's more complicated in vivo when virions also interact with the innate immune system 
(Dimmock, 2007). 
PRRSV can produce persistent infection due to the lack of virus neutralizing antibodies. 
Meier et al (2003) explored and quantified the kinetics of the immune response, by inoculating 
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intranasally 8 week old piglets with PRRSV. They found that virus neutralizing antibodies could 
only be detected at very low level in only half of the pigs eleven weeks post infection. Virus 
neutralizing antibodies reached their maximum titers twenty weeks post infection and started 
declining to where they were almost sero-negative by thirty-four weeks. Their study along with 
others (Nelson, 1994; Gonin, 1999) concluded that PRRS virus elicits a delayed and a poor 
neutralizing antibody response which is not affected by the virulence of the virus. As a 
consequence of this delayed immune response PRRS virus is not cleared during the early 
phase s of infection when , abundant viral replication, excretion, contact transmission and most 
of tissue damage takes place. 
The onset of NA after experimental infection is known to protect pigs against viremia but 
replicating virus were still found in the primary sites such as - tonsils, lungs and peripheral 
lymph nodes. Several serum transfer experiments have been done to deduce the importance of 
these NA’s. High titers at least 1:8 of virus neutralizing antibodies are required to stop the 
dissemination of PRRSV into the serum but at least neutralizing antibody titers of 1:32 are 
needed for complete protection of the animal against PRRSV infection (Lopez, 2007). Although 
neutralizing antibodies are not effective at clearing PRRS virus, it has been demonstrated that 
when present in high titers they protect against PRRS infection. When pigs were challenged 
with PRRS virus after being immunized with hyper immune sera containing high titers of 
neutralizing antibodies, it conferred protection. There was an absence of both viremia and 
reproductive failure 90dpi which is a hallmark of PRRSV infection. There was also a lack of 
vertical transmission of infection to the offspring’s since the piglets had normal viability at birth 
and survived unlike the pigs that didn't receive the PRRS virus antibodies. (Osorio, 2002). 
These results indicate that passively acquired antibodies play an important role in protecting 
sows against PRRSV infection. Correlation between the appearance of virus neutralizing 
antibodies in serum and elimination of infectious virus in blood has also been observed 
(Labarque, 2000). 
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Even though the role of neutralizing antibodies in vivo remains controversial, a few 
experiments by different labs showed a correlation between the antibodies and their role in 
protection at the animal level as well as at the cellular level. How these neutralizing antibodies 
might aid in protection against PRRS virus has been studied in-vitro in macrophages. PRRSV is 
believed to have very limited cell tropism in vivo and in vitro. In vivo, replicating PRRS virus is 
mainly found in well differentiated cells of the monocyte – macrophage lineage or especially in 
porcine alveolar macrophages (PAM). PAM's are the primary target cells of the virus but 
infection is also found in interstitial macrophages of other tissues such as heart, thymus, spleen 
etc. (Halbur, 1995; Beyer, 2000). PRRSV was originally isolated on primary cultures of PAM 
cells (Wenswoort, 1991) but since then another non-porcine permissive cell line consisting of a 
subclone of MA104 monkey kidney cells known as MARC-145 are routinely used for in vitro 
propagation and experiments with PRRSV (Benfield, 1992).  
In 1999, Nauwynck et al, confirmed the hypothesis that PRRSV entry occurs by receptor 
mediated endocytosis. With further investigation several receptors were discovered to play a 
role in PRRSV infection such as heparin sulfate for binding, sialoadhesion for binding and 
internalization (Delputte, 2002). Furthermore, the susceptibility of macrophages to PRRSV 
infection was associated with high expression of CD163, which is a molecule expressed 
exclusively on cells of monocytic lineage (Calvert, 2007; Lopez-Fuertes, 2000). Even though 
these receptors aided in the internalization it was found that both sialoadhesin (internalization 
receptor) and CD163 (involved in infection) are needed for a productive PRRSV infection of 
macrophages. Non-permissive cells expressing both of these receptors are more susceptible to 
infection and produce 10 to 100 times more virus compared with cells expressing only CD163 
(Van Gorp, 2008). 
Delputte etc. al. (2004) took these findings into consideration and on further investigation 
observed that porcine IgG purified from PRRSV infected swine serum effectively blocked 
infection of macrophages with PRRSV only when virus neutralizing antibodies were present in 
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the serum. Since serum from different days post infection were tested and only the serum that 
was collected 72dpi (i.e. when viral neutralizing antibody titers are higher and the other non-
neutralizing antibody concentrations are waning) was effective at blocking infection. They also 
observed through confocal microscopy this serum at 72dpi blocked virus attachment to the 
macrophages by 76% but mainly protected the cells against infection by almost completely 
blocking internalization (96%). As mentioned earlier, the main receptor that aided in 
internalization was sialoadhesin and therefore it can be hypothesized that neutralizing 
antibodies somehow interfere with the interaction between this receptor and the virus. Also, 
since the study used the cell type that is the prime target for PRRS virus and also the amount of 
IgG resembled the amounts found during natural infection, it can be hypothesized this method 
of inhibition of infection can also be seen in vivo.  
 
Neutralizing Epitopes  
 
Delputte et al. (2004) reported the antibodies that were produced 7dpi were mainly in 
response to the virus N protein but did not have any neutralizing activity. The 72dpi serum that 
had neutralizing abilities recognized the GP5 protein. This supported earlier finding that 
neutralizing antibodies in pigs are raised against the GP5 protein. This was first shown by 
Weiland et al (1999) when they were able to raise neutralizing antibodies in pigs which were 
inoculated with PAGE purified GP5 protein. Also when, pigs or mice were immunized with a 
plasmid DNA encoding the GP5 of PRRSV, both species were able to produce neutralizing 
antibodies and the pigs were also partially protected against a viral challenge (Pirzadeh, 1998). 
In similar experiments when pigs were immunized with insect cells infected with Baculovirus 
containing VR-2332 ORF5, partial protection to viral challenge was observed (Plana, 1997). In 
the above experiments, although GP5 seemed to have played an important role in the induction 
of neutralizing antibodies, contribution by other epitopes wasn't completely ruled out. 
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In PRRSV GP3 and GP4 proteins have also been recognized as neutralization epitopes. 
Experiments done with mouse monoclonal antibodies have led to the discovery of neutralizing 
epitopes in GP4 (Meulenberg, 1997) and GP5 (Weiland, 1999). In other studies it was 
hypothesized that antigenic regions might also be present in GP3. Although antigenic regions 
can be identified using monoclonal antibodies the immunogenicity of these epitopes can only be 
verified in pigs and there is substantial evidence pointing to the fact, there might be epitopes 
other than those on GP5 that play a role in inducing neutralizing antibodies. In a study designed 
to determine the specificity of the serum antibody response to the antigenic regions present in 
the envelope proteins in Lelystad virus infected pigs, antibodies against every separate AR were 
purified and their virus-neutralizing capacity was assessed (Nauwynck, 2011). It was observed 
the GP4 antigenic region was highly potent towards antibody mediated virus-neutralization and 
GP2 and GP3 were partially active. Moreover, neutralizing antibodies against GP4 appeared 
relatively early upon infection but antibodies against GP3 remained longer (Nauwynck, 2011). 
Osorio et al (2011), demonstrated that glycans on GP3, play a similarly important role as those 
of GP5 in protecting the virus from antibody mediated neutralization. This lends support to the 
notion that GP3 is also involved in inducing neutralizing antibodies. 
The envelope glycoprotein, GP4 is believed to have an immunodominant neutralizing 
epitope present in a hypervariable region (Meulenberg, 1997). As the region has a higher 
frequency of mutations it is believed that high immune selective pressure drives these amino 
acid changes. In pigs vaccinated or inoculated with PRRSV, neutralizing antibody escape 
mutants were isolated and found to contain changes in the GP4 epitope (Nauwynck, 2010). 
Grenfell and his colleagues (2004) have developed an interesting theory on such issues: they 
state that when immune pressure in the animal is either absent, low, or high, there is very little 
chance that immune escape variants will emerge. However, when immune pressure in the 
animal is intermediate at the onset of virus infection, substantial virus replication coincides with 
immune pressure, and can rapidly result in adaptation of the virus and selection of immune 
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escape variants. This lends further support to the fact that GP4 might also play a role in 
antibody mediated neutralization of the virus since there is such a high level of immune 
selective pressure acting on the site. 
 The involvement of the different PRRSV proteins and epitopes in the induction of virus-
neutralizing antibodies in pigs is yet to be completely resolved, as there is substantial evidence 
indicating the presence of unidentified neutralizing antibody targets in the PRRSV envelope 
proteins. In the case of a rapidly evolving RNA virus that can exist as quasispecies in the host, it 
makes sense to have multiple epitopes for the induction of neutralizing antibodies so that the 
virus could escape and be able to modulate the immune system. Also, as noted earlier a virus 
can be neutralized in a number of different ways, and it has been shown that GP2, GP3 and 
GP4 interact with each other to form a multiprotein complex that plays an important role in viral 
infectivity. Thus one can easily visualize how an epitope on either one of those proteins can play 
a role in neutralizing the virus by affecting any part in the assembly of the virion particle 
(Wissink, 2005). Even with the presence of other epitopes, the presence of a neutralizing 
antibody epitope in GP5 ectodomain is not questioned as this epitope has been investigated 
extensively.  
 
Glycoprotein 5  
  
Considerable evidence indicates GP5 bears a major virus neutralizing epitope. In a 
study comparing monoclonal antibodies against GP4 and GP5, it was shown that antibodies 
against GP5 were more effective at neutralizing the virus. For the complete neutralization of 
about 100 ID50 of PRRSV, anti-GP5 culture supernatant was effective up to a dilution of 1:1280 
compared to 1:64 dilution of anti-GP4 antibodies (Weiland, 1999). Also the time course for the 
formation of GP5 proteins and the appearance of neutralizing antibodies coincided with the 
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clearance of the virus from circulation (Rowland, 2003). These results indicate that GP5 is a 
major neutralizing epitope. 
A neutralizing epitope in GP5 was first recognized in other arteriviruses, specifically in 
Lactate Dehydrogenase Virus (LDV) (Plagemann, 2001). Antibodies to the GP5 neutralization 
epitope has been shown to be responsible for suppressing the replication of LDV, a closely 
related mouse arterivirus (Plagemann, 1999) and for controlling the replication of Equine 
Arterivirus in horses (Balasuriya, 1995). The primary neutralization epitope of VR2332 was 
identified by using overlapping GP5 ectodomain peptides of various lengths it was found that 
the antibodies recognized an epitope located in the middle of the ectodomain, from amino acid 
36-52. This is in the same relative segment that contains a neutralization epitope for the lactate 
dehydrogenase-elevating virus. It even shares a 77% amino acid homology with the 
corresponding GP5 ectodomain (Plagemann, 2002).  
The same epitope was also recognized in two other North American PRRS virus isolates 
by analyzing synthetic peptides that were generated on the basis of mimotope antibodies 
selected from a 12-mer phage display library (Ostrowski, 2002). In addition, they were able to 
separate the peptides that were recognized by the swine antibodies with high sero-neutralizing 
titer which came to be known as epitope B. Another epitope, epitope A (amino acid 27-30), was 
also identified which was recognized by anti-PRRSV serum but did not mediate virus 
neutralization. Epitope A was recognized early after PRRSV infection before any neutralizing 
antibodies could be detected in the serum, thus this epitope could not be involved in virus 
neutralization. However, epitope A is highly immunodominant during PRRSV infection and is 
suspected to act as a decoy epitope, eliciting most of the antibodies directed to GP5 and 
delaying the induction of neutralizing antibodies against epitope B. Moreover the increase in the 
titer of antibodies against epitobe B, three weeks post infection, correlates with a decrease in 
the concentration of antibodies against epitope A. Epitope B seems to be conserved between 
highly divergent north American PRRSV isolates, and residues H38 , I43, Y44, and N45 are the 
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main recognition sites whereas, residues 39 to 41 contribute to the binding of antibodies 
(Ostrowski, 2002). The glycans present on GP5 were thought to play a role in the low 
immunogenicity of epitope B.  
 The hydropathy profiles of the major envelope protein GP5, in North American PRRSV 
predict it has a signal sequence from amino acid 1 to 32, followed by an ectodomain from aa 33-
63, a transmembrane region from aa 64 – 134 and an endodomain from aa 135-200. Some of 
these amino acids are slightly different in European strains of PRRSV (Meng, 1995; Stadejek, 
2002). It also has a putative N terminal signal peptide and multiple potential N glycosylation 
sites have also been identified, the first potential glycosylation site is located in the 
hypervariable region at N34, the second and third are located at residues N44 and N51. Some 
strains of North American PRRSV also have a fourth potential N-glycosylation site at amino acid 
residue N30 (Faaberg, 1995; Dea, 2000; Plagemann, 2004). Biochemical assays of these 
glycosylation sites showed that high-mannose type sugar moieties were present at all three 
sites (Ansari, 2006). The PRRSV Gp5 protein is believed to form a disulfide-linked heterodimer 
with the viral Matrix protein (ORF 6) (Delputte, 2002). The formation of this heterodimer plays a 
critical role in the assembly of the PRRS virus. GP5 also is presumed to play a role in receptor 
recognition. It interacts with host cell receptor sialoadhesion for entry into porcine alveolar 
macrophages, the primary cells for infection (Delputte, 2004). The presence of a major 
neutralizing epitope and its role in receptor recognition shows that GP5 plays a significant role in 
the infection process.  
 
N-Linked Glycosylation  
 
The N-linked glycans found on GP5 might play a critical role in the proper functioning of 
the protein. N linked glycans are found attached to the R-group nitrogen (N) of asparagine. The 
sequon is a Asn-X-Ser or Asn-X-Thr sequence, where X is any amino acid except proline. N-
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linked glycosylations play an important role in correct folding, targeting and biological activity of 
proteins. Glycosylation is one of the most common post translational modifications that viral or 
cellular proteins undergo and it normally takes place on the luminal side of ER, before or during 
folding. Inhibition of N linked glycosylation often leads to defects at the level of folding and 
causes aggregated, misfolded, disulfide-crosslinked proteins that can't exit the ER. The effects 
and importance of each individual N-linked glycosylation site in any given protein varies (Doms, 
1993). The carbohydrate moiety of glycoproteins has been shown to have a large variety of 
different functions, such as protection against proteolysis, stabilization of protein conformation, 
receptor binding of microorganisms, clearance of proteins from the circulatory system, targeting 
in intra- and intercellular traffic, and cell-cell recognition as well as playing a role in modulation 
of proteins (Varki, 1993). In many enveloped viruses, the envelope proteins are modified by the 
addition of sugar moieties which are associated with a variety of functions such as receptor 
binding, mediation of membrane fusion, penetration into cells, virus budding and can also serve 
as antigens to elicit a protective immune response (Braakman, 2000). 
The membrane glycoproteins Gn and Gc of the Hantaan virus, like PRRSV, are modified 
by high mannose type sugars. There are six potential sites for the attachment of N-linked 
oligosaccharides; five of them are on the Gn and one of them on Gc. Through site directed 
mutagenesis it was found these N-glycosylation sites are crucial for the proper folding, 
intracellular transport and maintenance of epitope conformation but the importance of each 
individual glycan chain varied. Only five of the six sites were actually glycosylated. The first and 
third N-glycan site on Gn was found to be crucial for correct folding since without it, it was 
retained in the ER and unrecognizable by ant-Gn monoclonal antibodies. Single mutations and 
the lack of glycan at one of the other two sites in Gn or the one site in Gc were better tolerated 
and did not affect folding or targeting. Mutations of two N-glycosylation sites together; however, 
resulted in the loss of golgi targeting and could not be recognized by any of the three 
monoclonal antibodies (Shi, 2004). Similar affects to protein folding have also been seen in 
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vesicular stomatitis virus G protein (Machamer, 1988) and in influenza virus hemagglutinin 
protein (Gallagher, 1992). 
The significance of the N-glycosylation sites on GP2a and GP5 were similarly 
investigated in the PRRSV strain LV. There are two conserved N-glycosylation sites on each 
protein. Just like in previous experiments, through site directed mutagenesis, single and double 
mutant full lench PRRSV cDNA clones were generated and the proteins, as well as the 
production of mutant virus particles were compared to wild type. The results indicated the 
glycans normally present on GP2a, as well as one of the glycans on GP5 (N53) are not 
essential for viral particle formation. On the other hand, the other glycan position on GP5 (N46) 
was essential for virus particle formation. Viral infectivity was investigated by comparing 
infectivity-per-particle ratios with that of wild type ratios. Similar results were found where the 
two glycans on GP2a and N53 on GP5 had no effect on infection, through single or double 
mutations, whereas the absence of an oligosaccharide at N46 exhibited a significantly reduced 
infectivity as compared to the wild type virus (Wissink, 2004). Even though these glycans on 
GP2a and N53 on GP5 are not important for virus particle formation or infectivity, it cannot be 
dismissed that these glycans may play an important role in vivo, since they are conserved in 
both North American as well as European strains. 
One of the ways that glycans exert an effect in vivo is by affecting receptor binding, as 
can be seen in influenza virus hemagglutinin protein. Hemaglutinnin cannot bind to its receptor 
when the oligosaccharides next to the receptor binding site are sialylated in the absence of 
neuraminidase expression (Ohuchi, 1995). Eliminating the carbohydrate side chains adjacent to 
the receptor binding site increases the affinity of the influenza virus HA for its receptor to such 
an extent that release by receptor-destroying enzymes is severely impeded or completely 
inhibited (Ohuchi, 1997). Taken together these indicate oligosaccharides near the receptor 
binding site can modulate receptor specificity and avidity. Also the glycosylation sites on the 
hemagglutinin play a role in the biological activity as well as the antigenicity of the influenza 
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virus. Since the appearance of influenza virus in 1968 it has gained a few glycosylation sites in 
the globular head of hemagglutinin. Mutant viruses were made with one to six glycosylation 
sites on the globular head and all mutants seem to be transported to the cell surface as 
efficiently as wild type. Although, mutants with three to six glycosylation sites have decreased 
receptor binding activity, their cell fusion activity was not affected but the reactivity of these 
mutant viruses with human sera was lowered. Thus, the addition of these additional 
oligosaccharides has enabled the virus to evade antibody pressure by changing antigenicity 
without affecting its biological activity (Abe, 2004) 
 
Glycan Shielding - 
 
 It is evident, that glycosylation of viral envelope proteins due to selective pressure by the 
host is a major mechanism for viral immune evasion and persistence used by several different 
enveloped viruses to escape, block or minimize the virus neutralizing antibody response. 
Glycans are effective at escaping from immune effectors, because they are specified by the 
host rather than the viral genome. Thus they are considered self and tolerated by the immune 
system. The oligsosaccharides that are attached to the protein are typically highly hydrophilic 
branched chains of eight or more monosaccharide units designed to be exposed at the protein 
surface and with the capacity to cover a substantial portion of the underlying protein surface 
(Olofsson, 1992). This can be seen in the case of the Hepatitis C virus, which contains four and 
eleven N-linked glycans on their E1 and E2 proteins respectively. They play a major role in 
folding, viral entry and in modulation of the immune response. Even though the glycans have 
different roles, at least five of the glycans strongly reduced the sensitivity of the virus to antibody 
neutralization (Helle, 2010). The sugar moieties surround the neutralizing epitope in such a way 
that they restrict access to antibody, thus allowing the virus to persist. This is known as 'glycan 
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shielding' and has been shown in a number of viruses including influenza (Skehel, 1984) and 
human immunodeficiency virus (Wei, 2003). 
 There is evidence for glycan shielding in Arteriviruses as well. The viral envelope protein 
VP-3P (encoded by ORF 5) in lactate dehydrogenase-elevating virus (LDV is responsible for 
host cell receptor recognition and also carries a neutralization epitope which is surrounded by 
three large glycosylation sites. Neutralization escape variants had all three sites glycosylated 
which led them to conclude that these glycans impede the immunogenicity of the neutralization 
epitope, rendering the virus highly resistant to antibody neutralization. The middle glycosylation 
seemed to be an important determinant for persistent infection since when the virus only 
regained N-terminal glycosylation site it didn't gain the ability to cause persistent infection. Also 
the middle glycosylation site was conserved since all the variants regained it at the same site 
whereas the position of the N-terminal glycosylation site varied. However, no escape variants 
gained only the middle glycosylation site. Thus the N-terminal glycosylation site is likely to play 
a role in aiding neutralization escape, especially since the loss of both glycosylation site 
enhances the immunogenicity of the epitope and renders the virus very susceptible to antibody 
mediated neutralization (Chen, 2000). A similar mechanism many underly PRRSV virus ability 
to be impervious to host defenses.  
 Ansari et al. (2006) examined the importance of these N-linked glycosylations on the 
biological activities of PRSV GP5. They confirmed the finding that all three glycosylation sites 
had a high mannose type glycan moiety since they were sensitive to Endo H digestion. A fully 
glycosylated GP5 protein migrates at 25.5KDa whereas after being treated with EndoH, the 
protein is rendered unglycosylated and migrates at ~19KDa. Using reverse genetics, a series of 
mutant GP5 proteins were constructed where each glycosylation site was knocked out 
individually (N34, N44 and N51) as well as in various combinations. They were able to recover 
virus from constructs with the N44 site knocked were not able to recover viable virus indicating 
that this site is critical for recovery of infectious PRRSV. These results went hand in hand with 
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Wissink et al. (2004) that a mutation in the N46 of Lelystad PRRSV virus reduced infectious 
virus yield by hundred fold. Neutralization assays were done with viable virus constructs that 
lacking one glycosylation site at either N34 or N51 or in a combination where both the N34 and 
51 were knocked out. The mutant virus had an enhanced sensitivity to virus neutralization 
suggesting that removal of one or both glycan moieties increased the accessibility of the 
neutralizing epitope to specific antibodies (Ansari, 2006). Thus these glycan moieties do play a 
role in glycan shielding of GP5. 
 Although viable virus with the N44 site knocked out on the FL-12 backbone could not be 
recovered in vitro, a natural PRRSV isolate was found where the N44 site was knocked out and 
carried a serine (S) substitution that grew well in MA-104 cells and in pigs. During routine ORF 5 
sequencing of a thousand North American PRRSV isolates, twenty-one other isolates were 
detected that also had the N44 site knocked out (Ansari, 2006). Only two isolates were found 
that lacked the N51 site which grew well in the natural host but were unable to grow in BHK-21 
cells. Field isolates were also found with two glycosylation sites (N30 and N34) knocked out in 
the hypervariable region. A comparative study was done using these natural field isolates 
lacking the N-glyc site at N44, and in the hypervariable region and a fully glycosylated VR2332 
virus (Murtaugh, 2002). A group of young pigs were infected with either of the two types of virus 
and were bled periodically to assay their sera for neutralizing antibodies through direct and 
competitive ELISA using peptides containing the GP5 neutralization epitope. The neutralizing 
antibody response varied greatly between the pigs, some could generate high titers of 
neutralizing antibodies between seven to twenty-eight days post infection whereas other pigs 
did not generate response ninety days post infection. This may be attributed to genetic 
differences between pigs in their T helper and/or B cells (Murtaugh, 2002). Even with the 
difference in inducing neutralizing antibody titers within pigs, the pigs that were infected with the 
virus lacking glycans in the hypervariable region of the GP5 proteins were able to generate 
antibodies against the neutralization epitope more rapidly and to a five to ten times higher level 
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than VR2332 infected pigs. These neutralizing antibodies also neutralized the homologous virus 
ten to twenty times more efficiently than the other PRRSV strains. On the other hand, the pigs 
that were infected with the virus that had N-44 site knocked out generated neutralizing 
antibodies only forty-two days post infection and only to very low levels (Faaberg, 2006). These 
results suggested that the deletion of the N-glycans at the N terminal of the GP5 ectodomain 
affect the immunogenicity of the neutralization epitope.  
 Using mutant virus lacking glycosylation sites sensitive to anitbody mediated 
neutralization but investigators were also able to assertain whether virus lacking GP5 
glycosylation sites affects the ability of these viruses to induce higher titers of neutralizing 
antibodies in vivo. This phenomenon of removal of carbohydrate from viral envelope 
glycoprotein and establish the effects of induction of neutralizing antibodies in vivo had also 
been studied in HIV. Rhesus monkeys were infected with simian immunodeficiency virus 
mutants lacking selected glycan moieties. The removal of these carbohydrates led to induction 
of high titers of neutralizing antibodies in vivo. The mutant viruses were able to raise higher 
neutralizing antibody titers to the wild type virus than the wild type virus itself (Reiter, 1998). 
Similar results were seen with PRRSV, when pigs were infected with identical doses of wild type 
virus and the mutant viruses lacking the glycosylation site at either one or both site (Ansari, 
2006). Sequential samples of serum from these pigs for forty-eight days post infection with 
glycosylation mutants were obtained and the PRRSV serum neutralizing antibody response was 
quantified. There were pronounced differences between the wild type PRRSV and the mutant 
virus with mutant viruses inducing an early and more robust homologous neutralizing antibody 
response compared to the weak and delayed neutralizing antibody response induced by the 
wild type PRRSV. The neutralizing antibody response to the GP5 glycosylation mutant PRRSV 
was seen as early as fourteen day post infection as compared to three to four weeks post 
infection for the wild type virus. The GP5 glycosylation mutants induced a wild type PRRSV-
specific neutralizing antibody response that is significantly higher than the response with the 
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wild type PRRSV itself. The mutant viruses with glycosylation site knocked at only one site at 
either N34 or N51 induced a fivefold higher neutralizing antibody titer, whereas, the mutant virus 
with both sites knocked out induced a six fold higher neutralizing antibody titer (Ansari, 2006). 
The results when taken together show that the absence of glycan moieties at either N34 or N51 
or both in the GP5 ectodomain enhance both the sensitivity of these mutants to neutralization by 
antibodies and the immunogenicity of the nearby neutralization epitope.  
  This phenomenon was further investigated by constructing recombinant adenovirus 
expressing single or multiple N-linked glycosylation site mutant GP5 of PRRSV and evaluating 
their expression in cell culture and their potential to induce immune responses in BALB/c mice. 
For these experiments they looked at all four potential N-glycosylation sites on GP5 at N30, 
N34, N44 and N51. Six recombinant adenoviruses were constructed each expressing wild-type 
GP5 and four mutants: N44S, N44/51S, N30/44/51S, N30/33/44/51S and N30/33S. The 
removal of these glycosylation sites resulted in increased neutralizing antibody titers against 
PRRSV. Also with each additional removal of glycosylation site the titer of neutralizing antibody 
titer increased correspondingly. The titer of neutralizing antibody induced was also affected by 
the removal of N-glycans at N30 and N33. The titer of neutralizing antibody elicited by mutations 
in N30/33S was significantly higher than those elicited by GP5N44S, GP5N44/51S, and 
GP5N30/44/51S, but lower than that of GP5N30/33/44/51S. It indicated that the N-glycans at 
positions N30 and N33 might play a more important role in induction of neutralizing antibodies. 
They hypothesized that since antibodies against the decoy epitope could not be detected, the 
glycan at N30 and N33 might have inhibited the folding and exposure of the epitope thus 
decreasing the immune response to it which would also explain why Ansari et al. (2006) 
observed the mutants had a faster neutralizing antibody response than wild type. On the other 
hand, the glycans at N44 and N51 which are near the neutralizing epitope may play a role in 
transporting the protein to the cell surface thereby improving exposure to antigen presenting 
cells (Jian, 2007). Thus, it can be deduced that the glycans at N30 and N33 are responsible for 
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glycan shielding and removal of these glycans allows the neutralizing antibody to access the 
neutralizing epitope. 
 As a side note, even though both the above studies looked into the effects of glycan 
moiety at N30 on GP5, it has been well researched that the GP5 proteins contain a thirty amino 
acid N terminal putative signal sequence which is assumed to be cleaved (Mardassi, 1995). 
Since the N30 site would then get cleaved off, it would not be able to play a role in glycan 
shielding of the neutralization epitope, which is why we focused our study on the N34 glycan 
site in the hypervariable region of GP5. 
Like PRRSV, the neutralization epitope in the gp120 protein of HIV is conserved but it 
appears that the changes in the glycosylation sites surrounding the epitope are one mechanism 
leading to escape mutants. Wei et al. (2002) hypothesized that in the quaternary structure of the 
proteins, this glycan moieties act as a steric hindrance to the neutralization epitope. In the case 
of the HIV, the structure of the high mannose glycosylation which is found predominantly on 
HIV-1 is well suited to shielding since it has a trunk of mannose sugar extending from the 
protein surface before it branches out to a canopy of four to eight additional mannoses. But 
since the complete shielding of the epitope would interfere with receptor binding, it has to have 
holes in the shielding to allow for restricted access for functional purposes. Shifting the 
glycosylated site a little can selectively accommodate the receptor but not the antibody which 
allows the virus to restrict access to neutralizing antibodies thus causing neutralization 
resistance (Wei, 2002).  
One of the variable regions of the enveloped glycoprotein gp120 of HIV is the V3 loop 
which contains a prominent target for neutralizing antibodies. When the antibody sensitivity of 
the virus mutant lacking a single glycan in this V3 region was analyzed, it was found that the 
virus was neutralized 200 times better than the corresponding wild type virus by several 
monoclonal antibodies of the V3 region. Thus, this glycan somehow interfered with the effect of 
neutralizing antibodies. Mutants lacking this glycan site directed mutagenesis were created and 
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passed in cells without any selection pressure. Upon propagation of this glycan deficient virus 
mutant in the presence of neutralizing antibodies, variants were generated that were 
neutralization resistant. Within forty-eight hours of propagation, neutralization sensitive viruses 
were completely eliminated and only the resistant viruses were found in the population. Through 
sequence analysis and western blots, it was revealed that due to the selective pressure of the 
antibodies the viruses had regained the glycosylation site at the V3 region which had originally 
been eliminated (Schonning, 1992). Although this glycosylation site is present in a hypervariable 
region of the virus, it is present in 98% of all HIV-1 isolates sequenced (Myers, 1992) Thus, this 
glycosylation site is used for protection from the potentially neutralizing activity of antibodies and 
can be regained, but without it the virus is still able to function normally in the absence of 
immune selection pressures. 
A similar regain of glycosylation sites around the neutralizing epitope has also been 
seen in PRRSV. PRRSV-O1 was isolated from the field sample and the GP5 was sequenced as 
a part of the routine surveillance (Vu, 2011). The virus was then propagated in MARC 145 cells 
for multiple passages. After passaging in MARC 145 cells, the virus lost the glycosylation site in 
N131 of GP3 and N51 of GP5. Mutant viruses were also constructed with either one of the 
glycan sites missing or a combination of both. These mutants as well as the PRRSV-O1 were 
more susceptible to antibody neutralization and elicited greater neutralizing antibody response 
than the wild type PRRSV strain. These mutants as well as PRRSV-01 were inoculated into pigs 
and there was a rapid appearance of the N-glycosylation site in both GP3 and GP5 (Vu, 2011). 
The natural absence of N-glycosylation sites has been observed in other viruses such as the 
lactate dehydrogenase-elevating virus. The virus strains LDV-C and LDV-v naturally lack two N-
glycosylation sites in the primary envelope glycoprotein VP-3P. These strains are thus much 
more susceptible to antibody neutralization and elicit much greater neutralizing antibody 
response than the wild type strains that have glycan present at those sites. More importantly, 
the LDV-C and LDV-v strains regained the glycosylation sites after 2 or 3 passages in mice and 
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became resistant to antibody neutralization (Chen, 2000). It is very likely that the restoration of 
these glycosylation sites is a result of the strong selective pressure of the host immune system. 
 
Fitness  
 
There is considerable evidence to show that these N-linked glycosylation can vary due 
to immune pressures but there could also be other factors influencing these glycan sites, such 
as fitness. HIV gp120 has a range of possible N linked glycosylation sites of between 18 and 33 
with a mean of 25. It has been shown that the sequences in the V1-V2 envelope loop add 
glycosylation during the course of infection to alter the sensitivity to neutralizing antibodies 
(Sagar, 2006). Four patients were studied to compare the appearance of neutralizing epitopes 
and the glycans surrounding it in early viruses present at the time of acute infection, before any 
selective antibody pressure and viruses from a few years later. The median number of N-linked 
glycosylations sites was between 25 and 29 for early clones and 31 for later clones. 
Rearrangement of existent glycosylation sites were also seen and most of them occurred in the 
variable regions V1, V2 and V4 of the gp120, envelope glycoprotein. Another noteworthy 
observation was that in one of the four patients, the virus already had 31 N-glyc sites and the 
number didn't change throughout the infection process. The early and late viruses showed no 
difference in binding to the CD4 receptor binding site (Dacheux, 2004). It is possible, however, 
that there is a maximum number of N-linked glycosylation sites beyond which the virus risks 
losing some functionality or fitness. Since the median number of N-glycosylation sites at 31 was 
pretty consistent, and even though they made the virus less sensitive to neutralization, anything 
beyond that would affect other biological properties of the virus.  
Addition of glycans is due to selective immune pressure but the natural loss of these 
glycosylation sites might be driven by the lack of selective pressure but also by some other 
benefit gained from losing the glycan at the site. One of the potential benefits of losing the 
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glycan site is improvement in the fitness of the virus. In influenza virus, carbohydrates 
positioned around the globular head can mask antigenic sites from immune recognition. In 
H3N2 viruses, successive glycosylation events have potentially created a glycan shield that 
prevents accessibility and recognition of antibody (Abe, 2004). The addition of these 
carbohydrates of the globular head didn't negatively impact survival but it did result in some 
decrease to receptor binding without an effect on fusion activity. However, adding additional 
glycosylation sites to the lobular head of H2 HA does affect receptor binding and fusion activity. 
This at least partially explains why H2N2 viruses are seen infrequently and are present for a 
shorter period of time compared to the H1 and H3 influenza viruses (Tsuchiya, 2002). This 
suggests that in some cases the increase in carbohydrates reduces decreases the ability of 
influenza virus to replicate. Thus, there is a delicate balance between acquiring glycosylation 
sites to evade the immune system and not incurring a huge loss in fitness. 
The effect of the escape from neutralization antibody on fitness has been studied in 
Severe Acute Respiratory Syndrome (SARS), which belongs to the Coronaviridae virus family 
like PRRSV. Many studies have shown that the spike glycoprotein is a major component of 
protective immunity and contains more than three domains that are targeted by neutralizing 
antibodies. By doing a detailed analysis of the residues critical for neutralization by eleven 
different human monoclonal antibodies that differentially neutralized animal and human strains, 
and were able to find overlapping antigenic sites. The data also suggested that subtle changes 
in and around the antigenic site had an effect on antibody binding and a decreased sensitivity to 
neutralization. These escape amino acid mutations, also had an effect on kinetics of growth of 
the virus. The escape mutants grew to similar titers as the wild type but only after an initial delay 
in growth. It is hypothesized that this might be due to the reduced affinity for the receptor, thus 
delaying entry of the virus into the host cell. A few of the escape mutants also had a detrimental 
effect on the ability of the virus to grow in vitro suggesting that even though they can escape 
neutralization they are inefficiently maintained in the cell. An aged mouse model was used to 
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study the effects of the escape mutants in vivo. Except for one all the other escape mutants 
either partially or completely attenuated the SARS virus in the mice (Rockx, 2010). A decrease 
in virulence of neutralization escape mutants has also been observed in H5 and H9 influenza 
virus, which also end up having reduced affinity for the receptor (Ilyoushina, 2004). Thus escape 
from neutralization can sometimes also result in reduced viral fitness. 
In PRRS virus, when in vitro transcripts containing single and combined mutations in the 
N-glycan sites of GP5 were electroporated into MARC-145 cells, the growth kinetics of the 
recovered mutant viruses and the wild type virus were similar but the overall yield of the viruses 
containing a single N-glycan site knocked out at either N-34 or N-51 were approximately one log 
less than wild type in MARC-145 cells. While the virus, containing the double mutation that 
knocked out both the glycosylation sites at N34 and 51 had a titer of 1.5log less than the wild 
type. The virus was sequenced to make sure no other changes were introduced other than the 
desired mutations knocking out the respective glycosylation sites. Plaque assays were also 
done to compare the mutant viruses to the wild type PRRSV. The mutant viruses generated 
plaques that were less distinct and many of the cells within the plaques still appeared normal. 
Wild type PRRSV on the other hand, had larger, clear and distinct plaques and was able to 
clear the cell monolayer unlike the mutants. The mutant viruses were unable to lyse the cell 
monolayer and thus indicate that the recovered mutant viruses were less cytopathic than 
PRRSV. As mentioned earlier mutations knocking out the glycan site at N-44 on FL-12 GP5 
prevented recovery viable virus (Ansari, 2006). A similar study done by Jiang et al. (2007), 
showed similar results where recombinant adenovirus containing mutations at N44/51, 
N30/44/51, N30/33/44/51 and N30/333 grew slower than that expressing wild type GP5 and 
recombinant adenovirus carrying only mutation at N44 grew even slower. 
 Although, it seems like the glycans on the envelope protein, GP5, of PRRSV might play 
a crucial role in the biological activities of the virus, these fitness tests were all done in MARC-
145 cells that are not macrophages, the normal host cells of the virus. Even though there seems 
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to be a fitness cost to removing the glycans, the results could be different in vivo or in 
macrophages. 
Fitness differences depending on the host cell type used has been observed in other 
viruses. Nipah Virus is a deadly emerging paramyxovirus, which has two envelope 
glycoproteins, for attachment, Niv-G protein, and fusion, Niv-F, protein. Certain glycans on 
these envelope proteins are essential for proper conformational integrity and biological function. 
Aguilar et al., (2005) were able to show that the glycans on the Niv-F protein are not responsible 
for conformational integrity but they do protect the fusion proteins from neutralizing antibodies. 
Removal of these glycans, increased the virus sensitivity to antibody neutralization. However, 
they also found that virus strains lacking these glycans sites had increased membrane fusion 
and viral entry. They hypothesized that the presence of these N-glycans on the Niv-F protein 
reduced the rate of the six-helix bundle formation that is required for fusion. Thus, there is a 
contrasting role of the presence of these N-glycans on the fusion protein. This is a stark 
difference in the normal role of N-glycans on fusion proteins. With viruses such as Newcastle 
disease (Stone-Hulslander, 1995), measles (McGinnes, 2001) and Sendai virus (Segawa, 
2000), the removal of N-glycans results in severe defects in fusion. Thus, this is novel 
mechanism in which Nipah viruses can escape neutralization by the presence of these N-glyc 
sites, but adversely affect the fitness of the virus. This marked effect on the fusion kinetics of the 
Nipah virus was also affected by cell type. Slower fusion kinetics, when the N-glyc sites were 
present were most apparent in 293 T cells, slightly less apparent in Vero cells and least 
apparent in MDCK cells. These differences can be explained by the type and quantity of glycans 
added on by the different cells and also the difference in expression level in each cells. Western 
blotting of the Niv-F protein produced in 293 T cells versus the MDCK cells indicates that they 
migrate with slightly different mobilities which is suggestive of glycosylation differences (Aguilar, 
2006). Thus the cell types that are used in these comparison studies can make a marked 
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difference in the result. This highlights the fact that not all in-vitro phenomena are also occurring 
in vivo, in this case due to the difference in cell types.  
This differential effect of cell types has also been observed in the case of West Nile virus 
where the glycans present on one of the envelope proteins also have a detrimental effect on the 
biological activity of the virus. West Nile virus encodes two envelope proteins, premembrane 
(prM) and envelope (E). While the prM proteins of all West Nile viruses contain a single N-linked 
glycosylation site, not all strains contain an N-glyc site on the E protein. Although, these N-
glycan on the E protein till date hasn't shown any glycan shielding properties, the carbohydrate 
at this position can protect or mask the fusion loop of a partner E protein when in the homodiner 
conformation found on mature viruses (Mukhopadhyay, 2003). The presence of this glycan on 
the E protein also prevents irreversible conformational changes when exposed to acidic pH 
(Beasley, 2005). Therefore, while the presence of this N-glycan on the E protein is linked to 
beneficial advantages including more robust particle release due to more efficient protein 
folding, this same sugar moiety results in a modest reduction of initial infectivity. Lack of the 
glycan moiety on the E protein, results in an approximately three fold enhanced infectivity on 
BHK-21 and QT6 cells. West Nile virus can infect various different cell lines from different 
species - mammalian (BHK-21), avian (QT6) and mosquito cells (C6/36). When the infectivity in 
C6/36 was compared to the other cell lines, the presence of the glycan decreased infectivity in 
these cells 30-fold. Thus, the effect of glycosylation of E protein was far greater in mosquito 
cells than mammalian or avian. In mammalian cells, the reduction in infectivity can be offset by 
the efficient virus production whereas the absence of the glycan moiety in mosquito cells might 
be more severe (Hanna, 2005). Thus, these cell type dependent effects of glycosylation can 
play a significant role in determining the “fitness” of the virus.  
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Mutational Robustness  
Fitness, is a relative term and is dependent on the environment and the current state of 
the virus. A virus that is considered “fit” in one environment might not be in another, thus viruses 
are constantly evolving. As T. Dobzhanskly said “Nothing in biology makes sense except in light 
of evolution.” The basic principle behind evolution is survival. RNA viruses have a high mutation 
rate due to the lack of proof reading by their polymerases and, as seen with HIV, containing just 
the right number of glycosylation sites before they have a detrimental effect is indicative of the 
fact that, like most RNA viruses, they exist right at the brink of the error threshold. RNA viruses 
operating close to the error threshold doesn’t confirm, but is highly supportive of the existence of 
quasispecies. RNA virus populations do not have a homogenous genetic composition, and exist 
in a complex distribution of mutant genomes known as quasispecies. The quasispecies differ at 
various genomic sites, and a consensus sequence represents the average sequence at each 
genomic site whereas the master sequence represents the most fit members in a selected 
environment. As the environment changes, so may the master sequence as well as 
quasispecies population. Since viruses hardly ever experience a static environment, the ability 
to exist as a quasispecies increases the adaptability of RNA viruses and the fate of the 
population as a whole (Domingo, 2000). Current evidence indicates that quasispecies 
composition contributes to viral pathogenesis, modulate phenotypic traits, and include memory 
genomes which reflect the past evolutionary history. Genetic drift and shift, also act on the 
quasispecies population as a whole, to shape the long term evolution of viruses (Domingo, 
2006).  
The phenomenon of mutational robustness, can be seen under rapidly changing 
environments and can be best described as “survival of the fittest.” The best chance the virus 
has to survive is not by having one consensus genetic sequence but rather multiple variants of 
the genome so it can combat the varying environment (Sardenyes, 2008). This theory was 
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tested by limiting the genomic diversity of poliovirus. Ribavirin (mutagen that increases mutation 
frequency) resistant poliovirus carry a polymerase with enhanced fidelity, in turn reducing the 
genomic diversity of quasispecies. This resulted in the poliovirus unable to adapt to the 
changing environment, loss of neurotropism and attenuated pathogenic phenotype (Vignuzzi, 
2006). When the same poliovirus is allowed to replicate with a higher mutation rate, producing 
more complex quasispecies, pathogenesis is restored. We can predict that there is a 
cooperative interaction between these quasispecies, some mutants might help colonize the gut, 
others might help evade the immune system and yet others might be able to breach the blood 
brain barrier. The interactive variants together contribute to the phenotype of the population and 
the viral population as a whole is the target for selection (Vignuzzi, 2006). In essence the 
quasispecies theory describes how mutation and selection both act on a viral population and 
how these forces counterbalance each other (Domingo, 2000). 
A counterbalancing act between mutation and selection can be seen with variants that 
escape virus neutralization. Mutants that escape virus neutralization have mutations that enable 
it to do so, but with RNA virus genomes being so small there are several constraints that may 
limit the type and location of these mutations of the genome. As has been observed in earlier 
examples changing the presence of N-glycan site can have effects on various other properties 
of the virus, not just antibody mediated neutralization. Also monoclonal antibody mediated 
selection of escape mutants, deems those viruses more “fit” as they are able to produce 
progeny. Thus, fitness here is defined as the ability to produce progeny but the mutations that 
enable it to escape virus neutralization, can also be the mutations that have a fitness cost in the 
absence of a selective immune pressure. And, since most RNA viruses exist as quasispecies, 
with different fitness levels which coexist in infected organisms which are then subjected to 
selection by antibodies.  
Viral fitness plays a role in the selection of the escape variant when the entire virus 
quasispecies is under immune selection. Artificial quasispecies of foot and mouth disease virus 
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were made using two matched pairs of antibody resistant virus mutants which are comparable 
in their resistance to the antibody but differ in fitness by at least 11 and 13 fold. These virus 
quasispecies were then put under selection by different concentration of antibodies. Plaque 
development as a function of increasing concentration of antibody showed that each mutant of a 
matched pair yielded the same number of plaques, although the high fitness mutants required 
less time for plaque formation and attained a larger plaque size at any given time point. So even 
though the virus interacts with neutralizing antibodies identically and can resist neutralization, 
the higher fitness component of the mutant spectra has a higher probability of becoming 
dominant in the quasispecies compared to their low fitness counterparts (Martin, 2006). Thus, 
antibody selection acts on a mutant spectrum and RNA viruses with their memory genomes, 
and high mutation rates during genome replication dictate that these mutant spectra contain a 
repertoire of variants with similar antigenic profiles that differ in relative fitness (Drake, 1999).  
Keeping in mind, that fitness is relative to the current environment of the virus, the 
mutants that are “most fit” in the presence of neutralizing antibodies and the mutations that 
allow for this fitness might still be associated with a fitness cost under other conditions. Both of 
these effects together influence the composition of the selected mutant repertoire. A variant 
might first endure a high fitness cost imposed by an escape mutation but the mutant repertoire 
might contain other viruses that are just as antigenically effective at escaping the antibodies but 
are slightly less fit. On the other hand, it is also possible that the quasispecies might contain 
viruses that barely escape neutralization but are a lot more fit once the neutralizing antibody 
response subsides (Martin, 2006). Either way, in any type of selection event we are looking at 
more than one type of escape variants and the relative fitness of these variants determine which 
variant is dominant. 
In the end, it is a long term competition between hosts and viruses to evolve and gain an 
advantage over the other. It’s a game of fitness catch up, since both face constraints, it allows 
for competition and continuous improvement for all the players. As Van Valen (1973) best put it, 
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it’s a zero sum game, “no species can ever win and new adversaries grinningly replace the 
losers”. As Lewis Carroll (1872), had written, “it takes all the running you can do, to keep in the 
same place. If you want to get somewhere else you must run at least twice as fast as that.” In 
the scientific community this has largely come to be known as "the Red Queen hypothesis," 
because, species have to constantly "run" (evolve) in order to survive. Evolutionary change may 
be required to stay in the same place and the cessation of change may result in extinction. To 
survive all species have to evolve and the RNA viruses have a huge advantage because of their 
high mutation rates, rapid replication, large population size, and being able to control host cell 
environments. Then again hosts have found ways to combat these viruses too. Battles have 
been won by both viruses and hosts but the war continues to rage. So evolution is a natural 
phenomenon and for mankind to gain advantage it must constantly strive to understand the 
dynamics of evolution, the mutants and the selection pressures and accordingly manipulate and 
modify its own practices and where possible the biology of other living organisms to be mutually 
beneficial.  
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Chapter 3 
 
MATERIALS AND METHODS 
 
Cell and Media 
 
MARC 145 cells were propagated in Dulbecco's modified Eagle's medium (DMEM) 
containing 10% fetal bovine serum (FBS) and 100 units of penicillin, 20 units of streptomycin, 
and 20 units of gentamycin per ml of growth medium. These cells were used for virus infection, 
titrations and viral growth.  
ZMAC cells (Dr. Zuckermann, University of Illinois – Urbana Champaign) were 
maintained in RPMI 1640 medium without L-glutamine which is then supplemented with 10% 
FBS, 1 mM sodium pyruvate, 1X MEM non-essential amino acids, 25 mM HEPES, 4 mM L-
glutamine, 50 µg/mL of gentamicin sulfate, 4mM glucose and 5 µg/mL of MCSF. ZMAC cells 
were used for virus electroporation, viral infection, viral growth, titrations and neutralization 
assays. All cells were maintained at 37°C and 5% CO2. 
 
Generation of glycosylation site variants from the PRRSV FL-12 infectious clone. 
 
The full length PRRSV infectious cDNA clone (FL-12 in pBR322 served as the template 
for mutagenesis to introduce mutations at the potential N-linked glycosylation sites (N33, N34, 
N35, N34KO, N35KO) within GP5. Mutagenesis was carried out using overlap extension PCR 
with synthetic primers (Table 1), Pfx polymerase (Stratagene) and standard techniques. The 
PCR products were then digested with EcoRV and PacI which produced a ~3.3kbp fragment. 
This fragment was containing the mutations in the GP5 coding region was moved back into the 
full length PRRSV infectious cDNA clone using the same restriction enzyme sites. The GP5 
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coding region in the full-length clones was again sequenced with PRRSV-specific internal 
primers to confirm the presence of the mutations. 
 
In vitro transcription and electroporation and virus recovery. 
 
The full length plasmids were digested with AclI and linearized DNA was used as the 
template to generate capped RNA transcripts using the mMESSAGE mMACHINE Ultra T7 kit 
as per the manufacturer's (Ambion, Austin, TX) recommendations. The reaction mixture was 
extracted using the Rneasy Kits as per the manufacturer's (Qiagen) instructions. The integrity of 
the in vitro transcripts were analyzed by glyoxal-agarose gel electrophoresis followed by 
ethidium bromide staining. Transcript RNA was quantified using the nanodrop 2000 (Thermo 
scientific). 
ZMAC cells were electroporated with the transcripts with the aid of the Human 
Macrophage Nucleofector Kit (Lonza). About 2 × 106 cells were resuspended in 100µl room 
temperature nucleofector solution per sample which was then combined with approximately 
5.0µg of in vitro transcripts and 2µg of pmaxGFP vector. The samples were then transferred to 
a certified cuvette and using the Y-010 program in the Amaxa Nucleofector System the cells 
were electroporated. The electroporated cells were then transferred into a 12 well plate 
containing 1.5mL normal growth medium (complete RPMI). At 24H post electroporation, the 
GFP control was examined for fluorescence and the other wells for cytopathic effects which 
would indicate virus genome replication and transcription. Once virus replication was confirmed 
the supernatant was collected from electroporated cells and passed onto naïve ZMAC cells. The 
infected cells were observed for cytopathic effects and after 48hours the supernatant was 
collected and titered to confirm the presence of infectious virus. After confirmation, the virus 
stock was grown and frozen at −80°C in small aliquots for further studies. In all the experiments 
the FL-12 containing the wt PRRSV genome were used as controls.  
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Serum Neutralization Assay. 
 
Sensitivity to antibody neutralization of the constructed viruses will be evaluated using 
pooled homologous swine antiserum (provided by Dr. Osorio’s’ lab, University of Nebraska 
Table 2) in both ZMAC cells. A fluorescent focus neutralization assay for MARC cells and CPE 
for ZMAC cells was performed in triplicate to determine the titer of this swine antiserum against 
wild type FL-12 virus as well as the glycosylation mutant GP5 virus constructs. Non-parametric 
Wilcoxon Sign test were used to compare titers between constructs.  
 
 Analyses of proteins. 
  
 Marc-145 cells in a 6-well plate were infected with PRRSV. At 48h post-infection, cells 
were washed twice with phosphate-buffered saline (PBS) and starved in methionine and 
cysteine-free DMEM for 1 hour. Then radiolabeled with 0.6 ml of methionine and cysteine-free 
DMEM containing 100 uCi of Expre35S35S protein labeling mix (NEN Life Sciences, MA) per ml 
of medium for 3 hours. Following radiolabeling, the cells were washed in cold PBS three times 
and cell extracts were prepared in 300 _l of radioimmunoprecipitation assay (RIPA) buffer (10 
mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% Triton X-100, 0.1% sodium dodecyl sulfate [SDS], 1% 
sodium deoxycholate, and 1x protease inhibitor). The clarified cell extracts were incubated 
overnight at 4°C with rabbit anti-GP5 or anti-M protein antibody. A slurry of approximately 
4.0 mg of protein A-Sepharose (Pharmacia,Uppsala, Sweden) in 100ul RIPA buffer was added 
and further incubated for 2 h. The immunoprecipitated complexes were washed three times 
with 500ul of RIPA buffer. The immune-complex was resuspended in sodiumdodecyl sulfate- 
polyacrylamide gel electrophoresis (SDS-PAGE) sample loading buffer (50 mM 52Tris-HCl, pH 
6.8, 100 mM dithiothreitol, 2% SDS, 0.1% bromophenol blue, and 10%glycerol) and boiled for 5 
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min. After centrifugation at 16,000xg for 1 min, the proteins in the clarified supernatant were 
resolved by SDS-12% polyacrylamide gel electrophoresis (PAGE). Following electrophoresis, 
the gels processed for fluorography as described previously (Ansari et al. 2005). 
 
Viral Titrations 
 
Two-day-old confluent MARC-145 cell monolayers or 1x104/100 ml/well of ZMAC-4 cells 
were prepared in 96-well plates. Viruses were serially diluted 10-fold in DMEM supplemented 
with 10% FBS and antibiotic for MARC-145 cells and RPMI supplemented with 10% FBS, 1 mM 
sodium pyruvate, 1X MEM non-essential aminoacids and antibiotic for ZMAC-4 cells. Four 
replicate wells containing respective cells were inoculated with 100 µl of diluted sample. 
Inoculated cells were incubated for 3 days at 37°C/5% CO2 and examined for cytopathic effect 
(CPE). At the end of the 3-day incubation period, the MARC-145 cells were fixed in cold 
acetone: methanol (50:50) mixture for 10 min. The presence of PRRSV in the cells was 
confirmed by indirect fluorescent antibody (IFA) staining with SDOW17. For ZMAC-4 cells CPE 
was determined using optical microscope. Virus titers were calculated using the Spearman-
Kärber calculation based on the number of wells showing CPE or positive by the IFA test and 
expressed as TCID50/ml. Non-parametric Wilcoxon Sign test were used to compare virus 
neutralization titers between different PRRSV constructs.. 
 
Viral Growth Kinetics 
 
MARC-145 and ZMAC cells were infected with mutant or wt PRRSV at an MOI of 0.1 
PFU per cell and incubated at 37°C in an incubator. At various time points postinfection, aliquots 
of culture supernatants from infected cells were collected and the virus titer in the supernatants 
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was determined and expressed as 50% tissue culture infectious dose per ml (TCID50/ml). Non-
parametric Wilcoxon Sign test were used for statistical analysis.  
 
RNA extraction and RT-reaction 
 
RNA extraction is done using the Qiagen Viral RNA extraction kit as per the 
manufacturer’s instructions and the RNA is eluted in 50uL. Reverse transcription reaction was 
done using 2uL of RNA, 1uL dNTP mix (10mM), 1uL Random primer (300ng) and 9uL water 
and mixture was heated to 65°C for 5mins in thermocycler. After 5mins the tubes were 
incubated on ice for 1min and then 4uL of 5X First-strand buffer, 1uL DTT (0.1M), 1uL 
RNaseOUT (Invitrogen) (40units/uL) and 1uL of Superscript III (Invitrogen) (200units/uL) are 
added to bring the total volume of the reaction to 25uL. Tubes are mixed well by pipetting up 
and down; then incubated for 60mins at 50°C and then heated to 70°C for 15mins to inactivate 
the enzyme.  
 
Q-PCR reaction 
 
A cocktail of FL-12 Taq forward and reverse primers (Table 1) (0.75uL each or 150nM 
each), Probe for the Marker virus with FAM fluorophore (0.5uL or 100nM), Hotstar Taq Master 
mix (Invotrogen) (12.5uL), water (8.5uL) and 2uL of the RT reaction were mixed together to 
make a 25uL reaction. The same cocktail is made to recognize the competing virus using probe 
with MAX fluorophore using the same concentrations. The PCR plate was placed in the MJ mini 
Opticon for 30mins at 50°C, 15mins at 94°C, 15 sec at 94°C, 1min at 60°C, fluorescence is read 
and steps 3 to 4 were repeated for 39cycles.  
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Passaging virus in ZMAC cells under immune selection 
 
 Passaging the virus in ZMACs at low levels of neutralizing antibodies will introduce an 
immune pressure on the glycosylation mutant viruses. The virus was passaged in ZMAC at 
a dilution of 10-2 at the presence of varying levels of neutralizing antibodies in triplicates.  After 
24hpi, the wells in which the virus shows cytopathic effects at the highest dilution of neutralizing 
antibodies were collected and passaged. The virus was also be passaged without the presence 
of serum and in the presence of PRRSV negative serum. After 5 passages complete genome 
sequence of the passaged and inoculated virus was obtained using Sanger sequencing. 
Primers used to obtain the sequences are shown in Table 1 
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CHAPTER 4 
 
RESULTS AND DISCUSSION 
 
Codon Based Selection  
 
Studies conducted at the University of Nebraska sampled 67 PRRSV field isolates from 
1990 to 2005 in the upper Midwest USA and neutralization assays were done on reference 
antiserum – 1403-02, VR2332, Lelystad, MN 184, 97-7895 and 5424-00 (Vu, 2008). The results 
from this study indicated significant grouping of PRRSV field strains based on neutralization by 
these reference antisera (Vu Hiep, unpublished data). Using library construction and 
pyrosequencing methods developed by Alves et al. (unpublished data) we were able to obtain 
complete genomic sequence of the field strains. Analysis of these sequences showed that all 
but one of the N-glycosylation sites in the four PRRSV glycoprotein was invariant. We used the 
NetN-Glyc algorithm to predict the glycosylation site in the field strains we sequenced, and 
observed that the position of this predicted glycosylation site varied, with site present at amino 
acid residues 33, 34, or 35 (Figure 1A) whereas the epitope was identical in all cases. This 
positioning of the glycosylation site effectively moved the glycan shield either closer (N35) or 
further (N33) from the neutralizing epitope. Based on this observation, we then examined the 
association of that variation in glycosylation position on maximum virus neutralization titer of the 
vsrious anti sera. We found there appears to be a correlation between glycosylation site position 
and sensitivity of PRRSV to neutralization (Figure 1B). PRRSV strains with N35 glycosylation 
site appear to have a lower sensitivity to neutralization while those with N33 sites are more 
sensitive than strains with N34 glycosylation. 
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 Mutations within the coding sequence of a genome can be synonymous (no change in 
amino acids) or non-synonymous (substitution or deletion of an amino acid). The significance of 
synonymous changes is most often unknown but deletion of a protein more often than not 
results in a replication defective virus. Missense mutation are considered to be more important 
evolutionary changes since it may result in a codon that codes for a different amino-acid, 
rendering the resulting protein non-functional or of a higher fitness. The evolutionary relationship 
between sequences can also be determined by analyzing the number of synonymous and non-
synonymous changes between sequences. Basically if a non-synonymous change does not 
have an effect on the fitness of a virus then it is fixed within the population at the same rate as a 
synonymous mutation. In that case the non-synonymous to synonymous rate ratio would be 
neutral and equal to 1. If a non-synonymous mutation makes the protein more fit on average 
then the ratio would be greater than 1 and we can assume that it is unusually variable and has 
evolved through positive selection. If the opposite is true and the ratio is less than 1 then the site 
is unusually conserved and has been subject to purifying selection (Massingham, 2005). 
Codon based selection test was HyPity as implemented in Mega 5.0 (Tamura, 2011). In 
figure 2, the GP5 sequences from the field isolates were compared to look at differences in the 
epitope region. There is a high level of conservation in the epitope region as well as the 
sequence flanking the epitope region except for in the N34 glycosylation site. The non-
synonymous to synonymous ratio is also higher than 1 and compared to the surrounding 
sequence seems to be the only region with such a high ratio. This could suggest that the N34 
site is highly variable and under positive selection. 
 
Presence of glycosylation site 
 
 To study the effects of the variation in glycosylation site, various glycosylation mutant 
GP5 viruses were constructed (Figure 3) – N33, N34, N35 and N34Knockout (N34KO) – on an 
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FL-12 backbone. Since the variation between the different viruses were solely restricted to the 
glycosylation site and confirmed with sequencing, any differences in neutralization or fitness 
observed can be attributed to the changes in the glycosylation site. A fully glycosylated form of 
GP5 protein migrated at a mass of ~25.5kDa. Since each N-linked glycosylation adds ~2.5kDa 
of molecular mass to a protein, knocking it out should result in a reduction in size by that 
amount. We were thus able to determine if the introduced N33, 34, 35 and N34KO glycosylation 
sites were actually glycosylated (Figure 4). All GP5 proteins migrated at ~25.5KDa indicating 
that three sites were glycosylated. The N34KO GP5 migrated at ~23KDa confirming the loss of 
that glycosylation site. 
 
Evaluation of glycosylation site on sensitivity to antibody mediated neutralization 
 
 Direct evaluation of glycosylation site position on sensitivity to antibody neutralization 
was studied using serum neutralization assays in ZMACS. The findings from field isolates were 
expected to be replicated in vitro (ref). Neutralization titers were expected to be higher against 
the N33 mutant and lower against the N35 mutant as these are further or closer, respectively, to 
the neutralizing epitope. The N34KO was expected to give the highest neutralizing titer because 
of the lack of glycan shielding (Ansari, 2006). According to our results (Table 3) the change in 
glycosylation site from N34 to N33 did not render the virus more or less susceptible to antibody 
mediated neutralization. On the other hand, the change to N35 rendered the virus two logs more 
susceptible to antibody mediated neutralization and could explain why they are not abundant in 
nature. The gain or loss of glycosylation site did have an effect on the viruses’ vulnerability to 
antibody mediated neutralization. The N34KO virus with a knocked-out glycosylation site had a 
higher neutralization titer and thus more susceptible to neutralization than the viruses which had 
a glycosylation site present in that area.  
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 There could be many reasons why the shift in glycosylation site, especially closer in 
position to the neutralization epitope, might not have shown a difference in our in vitro 
experiments, one of which is antibody specificity. The serum used in the experiment was 
homologous to the FL-12 virus but not specific to the GP5 neutralization epitope. Also previous 
research has confirmed the presence of other neutralizing epitopes, which might be aiding in the 
neutralization of the virus. The different neutralization epitopes could be working together in 
order to neutralize the virus and therefore using a monoclonal antibody against the GP5 epitope 
would be a better way to confirm the effect of the variation in glycosylation site of GP5. 
Moreover, since the serum used for the neutralization assay was a pool of three other serums, it 
could decrease the magnitude of the neutralization titers. To further understand the variation in 
glycosylation and its effect on neutralization titers, the experiment needs to be repeated using 
multiple positive PRRSV antibody serum. Repeating the experiments in these different 
conditions would help to confirm the direct relation of the variation in glycan sites to neutralizing 
titers. 
 Another reason that could account for the variation in results from the field isolates and 
the virus constructs, is the cell type used to do the neutralization assay. For the field isolates, 
the neutralization assays were done in MARC-145 cells whereas for the experiments done with 
the virus constructs ZMAC cells were used. ZMAC cells have both the sialoadhesin and well as 
the CD163 receptor which makes them more susceptible to infection by PRRSV (Van Gorp, 
2008) than MARC 145 cells that only have the CD163 receptor (Duan, 1998). MARC 145 cells 
when pre-treated with anti-CD163 antibody at 0.3125µg reduced the frequency of infection from 
67% to 2% (Calvert, 2007). In PAMs’ when cells were treated with 5µg/100µl the overall 
infection rate dropped by 19.4% and when treated with 3µg/100µl the overall infection rate 
dropped by 8% (Patton, 2009). Sialoadhesin is the main receptor for internalization and the 
neutralization antibodies interfere with the interaction between virus GP5 epitope and the host 
(Delputte, 2004). Since MARC 145 cells only have the CD163 receptor which interacts with the 
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GP2a and GP4, the GP5 epitope might not play a role in neutralization of the virus in the MARC 
145 cells. To further look into the effects of neutralization titers and the variation in glycosylation 
site of GP5, experiments need to be repeated in both MARC 145 and ZMAC cell lines. Also 
repeating the growth curves and neutralization assays, by first pre-treating both the ZMAC and 
MARC cells with anti-CD163 antibody, will force the cells to use sialoadhesin receptor. Since 
the glycan shielding the GP5 epitope would normally interact with this receptor, one would 
expect the differences between the viral constructs to be amplified when blocking the other 
receptor in ZMAC cells. In MARC 145 cells blocking with anti-CD163 should block infection 
completely which could be an argument against using MARC cells for virus neutralization 
assays especially when looking into neutralizing antibody and GP5 interactions. On the other 
hand, if MARC cells were still able to induce a productive infection there could be other factors 
in play and would require further research. 
 
Passaging virus under immune pressure 
 
 Having confirmed that the lack of the glycan renders the virus more susceptible to 
neutralization, we wanted to see if the virus would regain the glycan site when placed under 
immune pressure as observed in vivo for the N44 site. When a virus lacking the glycan site at 
N44 was inoculated in pigs, they were able to induce the production of neutralizing antibodies 
more rapidly than VR2332 (Faaberg, 2006). The same was seen with virus constructs lacking 
the N34 or N51 site or in combination but when these viruses were inoculated in pigs they were 
able to rapidly regain the glycan site back (Vu, 2011). Along the same lines, we passaged the 
N34KO virus in the presence of varying amounts of neutralizing antibodies. The virus was 
passaged five times under these conditions (Figure 5a) and it was expected that the presence 
of the immune pressure would force the virus to regain the glycosylation site at N34. Even 
though the virus passaged in the presence of neutralizing antibody was less susceptible to 
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antibody mediated neutralization than the virus that was passaged in the absence of 
neutralizing antibodies, the virus sequences were all lacking the N34 glycosylation site (Figure 
5b). 
 In order to observe the actual changes in the glycan site at N34 of the GP5 protein, the 
virus might need to be passaged more than five times in the presence of neutralizing antibodies. 
Also there could also be compensatory changes in other structural proteins of PRRSV after 
passaging in presence of neutralizing antibody that could explain the difference in susceptibility 
to antibody mediated neutralization. The experiment would be continued with virus passaged 
multiple times and then sequenced using deep sequencing methods such as pyrosequencing. 
Using this method, the depth of sequencing will allow us to look at the quasi-species as 
compared to the consensus sequence. 
 Although we have confirmed that it is beneficial for the virus to have a glycosylation site 
at the N34 site, this is not the case always, and one would suspect there to be another factor 
influencing the site. It could even influence the variability in the position of the glycosylation site 
from N34 to N33 or N35. According to our experiments the variability could not be explained by 
immune pressure. One possible explanation is that the virus incurs some cost in terms of 
replicative fitness by increasing the glycan shielding on the GP5 neutralization epitope. Titers 
were calculated in each respective cell type and genome copies were determined using Real-
time PCR with SybrGreen probe (Table 4). Using the titers determined in each cell type, growth 
curves were done in triplicates in MARC145 and ZMAC cells at an MOI of 0.1 (Figure 6). The 
growth kinetics of all the virus constructs seem to be identical except for N35 which was slightly 
slower and lower than the other virus constructs. N34KO virus on the other hand had slower 
kinetics at first but caught up at 24hpi to the other constructs.  
 Growth curves are one way to compare the replicative fitness of the virus constructs. 
However, Competition assays are relatively more sensitive than growth curves to address the 
issue of replicative fitness differences between the different constructs. Competition assays 
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should be done relative to the FL-12 virus which has been modified in order to incorporate a 
series of four synonymous mutations (FL-12M) (Elena, 2003). This allows its differentiation from 
native FL-12 based on hybridization of Taqman probes. MARC 145 and ZMAC cell cultures 
should be co-infected with FL-12M and glycosylation mutant FL-12 virus at 1:1, 0.1:1, 0.01:1 
and 0.001:1respectively. After 4dpi in MARC 145 cells and 48hpi in ZMAC cells, culture 
supernatants can be harvested, clarified by low speed centrifugation and total RNA extracted 
and cDNA transcribed using standard methods. The relative abundance of glycosylation mutant 
FL-12 versus FL-12M genomes will be determined by taqman assay. The ratio of glycosylation 
mutant FL-12 to the reference zero passage FL-12M will determine the replicative fitness 
difference between the constructs. This method of comparing would be far more sensitive and 
informative about the replicative fitness difference of each virus. 
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CHAPTER 5 
 
CONCLUSION 
 
 This study attempts to demonstrate the importance of the presence of the glycosylation 
site at the hypervariable region before the GP5 neutralization epitope. The virus was more 
susceptible to antibody mediated neutralization in the absence of the glycosylation site. The 
presence of the glycan plays a role in glycan shielding of the epitope present on GP5 which 
were similar to the results observed by Ansari et al., (2006). The absence of the glycosylation 
site allows the neutralizing antibody to access the neutralizing epitope.   
 We, could not confirm, however whether the variation of the glycosylation site had any 
effect on the neutralization titer. Even though the virus was more susceptible to neutralization 
when the glycan position was at N35 then when it was at N33 or N34 in the in vitro experiments. 
The virus construct at N35 also had a mutation in the epitope region which could play a role in 
making the virus more susceptible. In order to confirm that the presence of a glycan at N35 
makes the virus more susceptible to neutralization, experiment would have to be repeating 
using a virus construct with a similar epitope sequence. If the virus construct with a similar 
epitope sequence and a glycan site at N35 showed a higher susceptibility to antibody mediated 
neutralization, it could explain why we see so few natural N35 viruses out in the field. 
The phenomenon of moving the glycan site closer to the epitope at N35 made the virus 
more susceptible and moving it further away to N33 from the epitope on GP5 made the virus 
less susceptible to neutralization was observed in the field isolates but  could not be repeated 
using the constructs. I already discussed the various ways the experiments could be modified to 
further understand the variation and its relationship to the neutralizing titer. It would also be 
beneficial to not only look at the viruses ability to be neutralized with the variation in 
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glycosylation site but also its ability to induce neutralizing antibodies. Even though the cells 
used in these experiments were a macrophage cell line, it would be interesting to see how these 
viral constructs fare in the natural environment of a pig.  
 As I have discussed in the literature review, there is never just one type of pressure 
acting on the virus at any given time. In its natural environment there might be multiple 
pressures acting in cohort with each other in such a way that the variation in glycosylation site 
might not aid the virus in escaping from immune pressure but by enhancing its ability 
somewhere else in the virus replication cycle. Further experiments would need to be done in 
order to identify the external factors acting on this site.  
 We also didn’t see a replicative fitness difference associated with the variation in 
glycosylation site of the virus. As I have mentioned, growth curves are not the ideal way to 
compare different viruses and it would be in the best interest to design co-infection experiments 
that could better enhance our understanding of this phenomenon. Also studying the various 
aspects of the virus replication cycle such as attachment and internalization might also give us a 
more in depth understanding at whether these variations affect the viral fitness.  
 When the N34KO virus was passaged in the presence of neutralizing antibodies it was 
less susceptible to antibody mediated neutralization but it did not regain the glycosylation site at 
N34. The situation is complex when the immune pressure in the host is intermediate and forces 
the emergence of escape variants. In order to replicate this in vitro, further experiments need to 
be done using varying amounts of neutralizing antibody. We might also see a difference if the 
time the virus is exposed to the neutralizing antibody is varied or even when the virus is 
collected for passaging. Varying the MOI of infection and passaging the virus for a longer time 
could all play a role in affecting these results. With more time and background work, the 
experimental design could be improved and made more sensitive so that the virus is forced to 
mutate and generate escape variants which could then be identified as the consensus 
sequence. 
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 Sequencing the entire genome of the virus through deep sequencing methods such as 
pyrosequencing would also let us look at the quasispecies population and see the slight 
changes that might appear within the GP5 epitope or even somewhere else in the genome. The 
virus genome can have changes in its other structures that might be working together; therefore 
you would be able to see compensatory changes within the genome.  
 The beauty of these experiments was using an FL-12 backbone and conducting the 
experiments with minimum passaging in cells. This allowed a consensus genome with only the 
changes that were artificially introduced in the glycosylation site of GP5.  Hippocrates was 
correct in his aphorism that "description is infinite and easy; explanation is limited and difficult" 
but the results of this research provide a better understanding of the presence of the 
glycosylation site at N34 and its relationship to neutralizing titers.  
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CHAPTER 6 
 
FIGURES AND TABLES 
 
Figure 1. Variation in position of glycosylation sites influences sensitivity of PRRSV to serum 
neutralization. 1a. Predicted glycosylation predicted by the n-glyc algorithm. 1b. Out of the 
sample taken unambiguous sites max titer that any anti sera gave against them increased as 
the glycosylation site moved away from the epitope. 
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Figure 2. Variation in N-glycosylation sites of GP5. The N-glycosylation sites at N44 and N51 
are highly conserved compared to the N-glycosylation site at N34. Usually, most non-
synonymous changes would be expected to be eliminated by purifying selection, but under 
certain conditions Darwinian selection may lead to their retention.  Investigating the number of 
synonymous and non-synonymous substitutions may therefore provide information about the 
degree of selection operating on a system. Using the ratio of non-synonymous to synonymous 
ratio (dN/dS) when greater than one shows selection acting on that particular area. 
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Figure 3. Design for creating viral constructs.  
 
 
 
Restriction digest with 
EcoRV and PacI 
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Figure 4. Confirmation of N-glycosylation site on GP5 mutant virus constructs. 4a. Schematic 
representations of the genomes of virus FL-12 and mutants derived from it. The letter N in the 
red colour and the number above it represent the glycosylation site for each respective virus 
and the lighter colours are the artificially induced changes from the wild type. 4b. Electrophoretic 
mobility of GP5 wild type and the mutant viruses. MARC-145 cells were mock infected or 
infected with the indicated virus. At 36 h postinfection, proteins were radiolabeled as described 
in Materials and Methods and immunoprecipitated with anti-GP5 antibodies. 
 
4a       4b. 
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Figure 5. N34KO Virus passaged in the presence of neutralizing antibodies. 5a. Experimental design to passage virus five times in 
the presence of neutralizing antibodies. 
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Figure 5a (cont.) 
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Figure 5b. Sanger sequencing results of N34KO virus, passed five times in the presence of 
neutralizing antibodies in ZMAC, demonstrating no sequence change in the glycan site or 
flanking areas. 
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Figure 6. Effects of the absence of N-glycosylation sites GP5 on the in vitro growth properties in 
ZMAC cells. Growth curves of the indicated viruses upon infection of ZMAC cells at an MOI of 
0.1. Viral titers are expressed as means ± standard errors of the means (SEMs) (error bars) of 
data obtained from three independent experiments. 
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Table 1. Primers. Bold letters denote the sequence changes from the FL-12 wild type virus.  
 
 
Primer Name     Sequence 
Gly33_For   GCT CGT CAA CGC CAG CAA CAG CAG CAG CTC TCA TCT TCA G 
Gly33_Rev   AAC TGA AGA TGA GAG CTG CTG CTG TTG CTG GCG TTG ACG AGC GCA G 
Gly34_For   CTC GTC AAC GCC AGC AGC AAC AGC AGC TCT CAT CTT C 
Gly34_Rev   AAC TGA AGA TGA GAG CTG CTG TTG CTG CTG GCG TTG ACG AGC GCA GC 
Gly35_For   GTC AAC GCC AGC AGC AGC AAC AGC TCT AAA CTT CAG TTG ATT TAC 
Gly35_Rev   GTA AAT CAA CTG AAG TTT AGA GCT GTT GCT GCT GCT GGC GTT GAC 
Gly34KO_For   GCC AAC AGC GCC AGC AGC TCT C 
Gly34KO_Rev   GAG AGC TGC TGG CGC TGT TGG C 
GP5_BsrGI-For   CGC CCG TGT ACA TCA CTG TCA CAG CCA ATG 
GP5_BstEII-Rev 
CGA TCA GGT GAC CTT CGA CCT CAA CCT TAC CC 
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Table 2. Serum Neutralization results for the swine serum used for neutralization. This is the 
serum Neutralization result of all serum samples at 49 and 60 dpi against FL12wild type virus. 
Each assay is repeated twice in MARC 145 cells and all three serums were pooled together for 
experiments.  
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Table 3. Virus Neutralization Assay in ZMAC cells. Plates were evaluated 48 hours post 
infection by cytopathic effects. Each result is an average of three replicates. 
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Table 4. Effects of positive immune selection on glycosylation mutant virus. After passaging the 
virus, neutralization assays were conducted in ZMAC cells and evaluated 48 hours post 
infection by cytopathic effects. The virus passaged in the presence of neutralizing serum 
became less susceptible to neutralization after passaging than the virus that was passaged 
without any immune pressure.  
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Table 5. Titers and C(t) values. Titers were calculated in each respective cell type. After 5dpi in 
MARC 145 plates were evaluated using immunofluorescence and in ZMAC cells 3dpi, plates 
were evaluated by cytopathic effects. Genome copies were determined by using Real-time PCR 
with SybrGreen probe on extracted RNA (Qiagen kit) from virus samples.  
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